You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
MELVILLE, N.Y., Apr 29, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the...
MELVILLE, N.Y., Apr 26, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing...
First Maintenance Therapy Approved For a Broad Patient Population Including Squamous and Non- Squamous Histology MELVILLE, N.Y., Apr 16, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ:...
Survey Reveals Pervasive Donation Myths RICHMOND, Va. (April 5, 2010) – According to a new survey by Donate Life America, 43 percent of people are undecided, reluctant or do not wish to have...
MELVILLE, N.Y., Mar 19, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its international partner for Tarceva(R) (erlotinib), Roche, informed OSI that the...
Follow U.S. news
